Antimabotanica - Company finances
|
EUR
|
2020
From: 2020-10-29
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | - | 24,174 | 43,926 | 49,720 | 55,676 | 69,688 |
| Profit before tax | -34 | -13,519 | 10,423 | 3,792 | 600 | -1,630 |
| Net profit | -34 | -13,519 | 10,423 | 3,761 | 111 | -1,630 |
| Equity | -33 | -13,552 | -3,129 | 632 | 743 | -887 |
| Liabilities | 34 | 26,031 | 29,053 | 19,017 | 9,576 | 30,313 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 3,336 |
| Current assets | 1 | 12,479 | 25,924 | 19,649 | 10,319 | 26,090 |
| Total assets | 1 | 12,479 | 25,924 | 19,649 | 10,319 | 29,426 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | - | 31 | 4,598 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | - | +81.7% | +13.2% | +12.0% | +25.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -3400.0% | -108.3% | 40.2% | 19.1% | 1.1% | -5.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | 595.1% | 14.9% | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | -55.9% | 23.7% | 7.6% | 0.2% | -2.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | -55.9% | 23.7% | 7.6% | 1.1% | -2.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 30.1 | 12.9 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Antimabotanica - Social security debts
The amount of overdue SODRA debt for the company Antimabotanica as of the last working day is: 80 €
| From | To | Debt, € |
|---|---|---|
| 2026-09-05 | 2026-09-15 | 80.47 |
| 2026-08-27 | 2026-09-02 | 80.47 |
| 2026-08-26 | 2026-08-26 | 38.10 |
| 2026-08-23 | 2026-08-23 | 80.47 |
| 2026-08-19 | 2026-08-19 | 80.47 |
| 2026-08-16 | 2026-08-17 | 80.47 |
| 2026-08-01 | 2026-08-14 | 80.47 |
| 2026-07-01 | 2026-07-31 | 272.09 |
| 2026-06-02 | 2026-06-30 | 191.61 |
| 2026-05-03 | 2026-06-01 | 111.13 |
| 2026-04-01 | 2026-04-30 | 30.65 |
| 2025-07-09 | 2025-07-31 | 210.77 |
| 2025-06-17 | 2025-07-08 | 249.11 |
| 2025-06-03 | 2025-06-16 | 297.74 |
| 2025-05-04 | 2025-06-02 | 225.29 |
| 2025-04-01 | 2025-04-30 | 152.84 |
| 2025-03-04 | 2025-03-31 | 80.39 |
| 2025-03-03 | 2025-03-03 | 7.94 |
| 2025-03-01 | 2025-03-02 | 80.39 |
| 2025-02-01 | 2025-02-28 | 7.94 |
| 2024-08-01 | 2024-08-31 | 128.99 |
| 2024-07-02 | 2024-07-31 | 64.49 |
| 2023-03-01 | 2023-03-31 | 180.13 |
| 2023-02-01 | 2023-02-28 | 121.50 |
| 2023-01-03 | 2023-01-31 | 62.87 |
| 2022-12-28 | 2023-01-02 | 11.92 |
| 2022-12-01 | 2022-12-27 | 62.87 |
| 2022-11-29 | 2022-11-30 | 11.92 |
| 2022-11-03 | 2022-11-28 | 62.87 |
| 2022-10-06 | 2022-11-02 | 11.92 |
| 2022-10-03 | 2022-10-05 | 62.87 |
| 2022-09-01 | 2022-10-02 | 11.92 |
Antimabotanica - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Antimabotanica is: 1,147 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-01 | 2026-09-02 | 1146.62 |
| 2026-08-31 | 2026-08-31 | 1143.72 |
| 2026-08-30 | 2026-08-30 | 1143.75 |
| 2026-08-29 | 2026-08-29 | 3260.58 |
| 2026-08-02 | 2026-08-28 | 3363.82 |
| 2026-07-26 | 2026-08-01 | 467.79 |
| 2026-07-01 | 2026-07-25 | 464.67 |
| 2026-06-30 | 2026-06-30 | 464.02 |
| 2026-06-28 | 2026-06-29 | 464.04 |
| 2026-05-28 | 2026-05-28 | 283.6 |
| 2026-04-03 | 2026-04-23 | 2.7 |
| 2026-04-01 | 2026-04-02 | 1763.51 |
| 2026-03-27 | 2026-03-31 | 20.81 |
| 2026-03-22 | 2026-03-26 | 57.93 |
| 2026-03-20 | 2026-03-21 | 2323.38 |
| 2026-03-11 | 2026-03-17 | 943.59 |
| 2026-03-08 | 2026-03-10 | 2401.37 |
| 2026-03-02 | 2026-03-07 | 1458.89 |
| 2026-02-27 | 2026-03-01 | 23.78 |
| 2026-02-13 | 2026-02-26 | 11.56 |
| 2026-02-03 | 2026-02-12 | 3883.5 |
| 2026-01-29 | 2026-02-02 | 4075.62 |
| 2026-01-23 | 2026-01-28 | 0.62 |
| 2026-01-09 | 2026-01-22 | 1051.32 |
| 2026-01-01 | 2026-01-08 | 1184.68 |
| 2025-12-30 | 2025-12-30 | 14.44 |
| 2025-12-24 | 2025-12-29 | 1995.04 |
| 2025-12-12 | 2025-12-23 | 1987.88 |
| 2025-12-10 | 2025-12-11 | 1988.18 |
| 2025-12-01 | 2025-12-09 | 1983.5 |
| 2025-11-28 | 2025-11-30 | 1980.91 |
| 2025-08-01 | 2025-08-23 | 6.79 |
| 2025-07-31 | 2025-07-31 | 5.47 |
| 2025-07-25 | 2025-07-30 | 835.36 |
| 2025-07-10 | 2025-07-24 | 1073.22 |
| 2025-07-01 | 2025-07-09 | 1148.44 |
| 2025-06-30 | 2025-06-30 | 1148.13 |
| 2025-06-28 | 2025-06-29 | 1146.63 |
| 2025-06-24 | 2025-06-27 | 489.63 |
| 2025-06-22 | 2025-06-23 | 489.24 |
| 2025-06-19 | 2025-06-21 | 488.98 |
| 2025-05-06 | 2025-05-13 | 13.72 |
| 2025-05-03 | 2025-05-05 | 525.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Antimabotanica, MB (code 305649796) is a Lithuanian small partnership operating in other non-specialised retail sale. In 2025, the latest financial year, the company generated revenue of €69.7K, up 25.2% year on year and 40.2% over two years. Despite the top-line growth, profitability weakened materially. Net profit was €3.8K in 2023, only €111 in 2024, and then turned into a €1.6K loss in 2025, resulting in a negative profit margin of 2.3% for the year. The balance sheet also deteriorated in 2025: total assets were €29.4K, liabilities €30.3K and equity fell to -€887, indicating that obligations exceeded assets. Short-term assets accounted for most of the asset base, while long-term assets were €3.3K. Asset turnover was 2.37x, showing relatively efficient use of assets to generate revenue, but the negative equity position and loss-making result point to weaker financial stability. No staff data was provided, so revenue per employee cannot be assessed.